Oramed Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Oramed Pharmaceuticals

09/05/2024 23:38

* Oramed Pharmaceuticals Inc  ORMP.OQ  reported quarterly
adjusted
earnings of 4 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -8 cents.  The lone analyst forecast for the
quarter was for earnings of 2 cents per share. 
    * Reported revenue was zero​; analysts expected $500.00
thousand. 
    * Oramed Pharmaceuticals Inc's reported EPS for the quarter
was 4
cents​.
    * Oramed Pharmaceuticals Inc shares had fallen by 16.8% this
quarter and gained 5.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Oramed
Pharmaceuticals Inc is $4.25 

This summary was machine generated from LSEG data May 9 at 10:37
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024                     0.04           
 Dec. 31 2023      -0.12          0.33           Beat
 Sep. 30 2023      -0.08          -0.08          Met
 Jun. 30 2023      -0.10          -0.03          Beat